The study will assess atacicept vs. placebo on the impact of renal function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period.
The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.